Durvalumab (Imfinzi®). HTA ID: 23009

Assessment Status Rapid Review Complete
HTA ID 23009
Drug Durvalumab
Brand Imfinzi®
Indication Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer.
Assessment Process
Rapid review commissioned 20/02/2023
Rapid review completed 16/03/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of durvalumab used in combination with gemcitabine and cisplatin compared with the current SOC (gemcitabine and cisplatin).